What's Happening?
A recent study published in the journal Nature Metabolism has revealed that glucosamine, a common supplement used for joint pain and arthritis, may accelerate memory loss in individuals with Alzheimer's disease. Researchers at the University of Florida
analyzed anonymized medical records of 24,000 patients with dementia and 41,000 with mild cognitive impairment. They found that Alzheimer's patients who took glucosamine were 25% more likely to die within five years compared to those who did not take the supplement. Additionally, individuals with mild cognitive impairment taking glucosamine were 25% more likely to progress to full Alzheimer's. The study also included experiments on mice engineered to have Alzheimer's-like symptoms, which showed that glucosamine worsened memory loss in these mice.
Why It's Important?
The findings of this study are significant as they challenge the common perception of glucosamine as a safe supplement for joint health. With over 40 million Americans using glucosamine annually, the potential risks for those with cognitive decline are concerning. The study suggests that while glucosamine may be safe for healthy individuals, it could be harmful to those already experiencing cognitive issues. This raises important questions about the regulation and labeling of dietary supplements, which are not subject to the same rigorous testing as prescription drugs. The research highlights the need for further investigation into the effects of glucosamine and similar supplements on cognitive health, particularly for the aging population.
What's Next?
Future research is needed to establish a causal relationship between glucosamine and cognitive decline. The researchers plan to conduct a clinical trial on patients who have discontinued glucosamine to observe if stopping the supplement slows cognitive decline. Additionally, they aim to explore other compounds that might reduce sugar buildup on brain cells, potentially slowing or reversing Alzheimer's disease. The study also calls for examining other supplements that may pose similar risks to individuals with cognitive impairments.
